<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01223131</url>
  </required_header>
  <id_info>
    <org_study_id>EFC11681</org_study_id>
    <secondary_id>U1111-1116-3661</secondary_id>
    <nct_id>NCT01223131</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Insulin Glargine Versus. Neutral Protamine Hagedorn (NPH) Insulin in Children With Type 1 Diabetes Above 6 Years Old.</brief_title>
  <acronym>Lantus-P-CN</acronym>
  <official_title>A 24-week, Randomized, Open-label, Parallel Group, Multicenter Comparison of LantusÂ® (Insulin Glargine) Given Once Daily Versus Neutral Protamine Hagedorn (NPH) Insulin in Children With Type 1 Diabetes Mellitus Aged at Least 6 Years to Less Than 18 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

      6 To assess the efficacy of insulin glargine given once daily (QD) on glycosylated hemoglobin
      (HbA1c) levels over a period of 24 weeks in children with type 1 diabetes mellitus (T1DM)
      aged at least 6 years to less than 18 years.

      Secondary Objectives:

        -  To assess the effects of insulin glargine compared to NPH insulin over 24 weeks on:

             -  Percentage of patients reaching International Society of Pediatric and Adolescent
                Diabetes (ISPAD) recommended target of HbA1c &lt; 7.5%,

             -  Fasting blood glucose (FBG),

             -  Nocturnal blood glucose (BG),

             -  24-hour blood glucose profile based on 8-point self-monitoring of blood glucose
                (SMBG) values,

             -  Daily total insulin dose and basal insulin dose,

             -  Rates of asymptomatic and/or symptomatic, severe, nocturnal and nocturnal
                symptomatic hypoglycemia.

        -  To assess the safety and tolerability of insulin glargine versus NPH insulin based on
           the occurrence of treatment-emergent adverse events (TEAEs).

        -  To assess anti-insulin and anti-glargine antibody development in both groups.

        -  To assess insulin glargine pharmacokinetic(PK) for all patients treated with insulin
           glargine in selected sites with approximately 45% of insulin glargine population to rule
           out accumulation tendency of insulin glargine after repeated dosing
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study duration for each patient is 28 weeks +/- 7 day broken down as follows:

        -  Screening phase: up to 2 weeks

        -  Run-in phase: 1 week

        -  Treatment phase: 24 weeks

        -  Follow-up: 1 week
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute change of glycosylated hemoglobin (HbA1c)</measure>
    <time_frame>from baseline to week 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients reaching HbA1c &lt; 7.5%</measure>
    <time_frame>at week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Blood Glucose (FBG)</measure>
    <time_frame>from baseline to week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in nocturnal Blood Glucose (BG)</measure>
    <time_frame>from baseline to week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 24-hour blood glucose profile based on 8-point self-monitoring blood glucose (SMBG)</measure>
    <time_frame>from baseline to week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in total insulin dose and basal insulin dose</measure>
    <time_frame>from baseline to week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of asymptomatic and/or symptomatic, severe, nocturnal, nocturnal symptomatic hypoglycemia.</measure>
    <time_frame>during 24-week treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-glargine and anti-human insulin antibody assessment</measure>
    <time_frame>at screening, week 4, week 24</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">162</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Insulin glargine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>injection once daily at bedtime</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NPH insulin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>injection once daily at bedtime or twice daily in the morning and at bedtime</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin glargine (HOE901)</intervention_name>
    <description>Pharmaceutical form:aqueous solution for injection
Route of administration: Subcutaneous</description>
    <arm_group_label>Insulin glargine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NPH insulin</intervention_name>
    <description>Pharmaceutical form:aqueous solution for injection
Route of administration: Subcutaneous</description>
    <arm_group_label>NPH insulin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        - Paediatric patients diagnosed with T1DM aged at least 6 years to less than 18 years at
        screening.

        Exclusion criteria:

          -  Treatment with oral or parenteral glucose-lowering medications other than insulin.

          -  HbA1c &lt; 7% or &gt; 12 % at screening.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site Number 156006</name>
      <address>
        <city>Beijing</city>
        <zip>100020</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 156001</name>
      <address>
        <city>Beijing</city>
        <zip>100045</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 156007</name>
      <address>
        <city>Beijing</city>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 156009</name>
      <address>
        <city>Changsha</city>
        <zip>410011</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 156008</name>
      <address>
        <city>Guangzhou</city>
        <zip>510630</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 156004</name>
      <address>
        <city>Hangzhou</city>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 156016</name>
      <address>
        <city>Shanghai</city>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 156005</name>
      <address>
        <city>Shanghai</city>
        <zip>201102</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 156019</name>
      <address>
        <city>Taiyuan</city>
        <zip>030013</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 156002</name>
      <address>
        <city>Wuhan</city>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 15, 2010</study_first_submitted>
  <study_first_submitted_qc>October 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 18, 2010</study_first_posted>
  <last_update_submitted>March 31, 2014</last_update_submitted>
  <last_update_submitted_qc>March 31, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 1, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Isophane insulin, beef</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
    <mesh_term>Insulin, Isophane</mesh_term>
    <mesh_term>Isophane Insulin, Human</mesh_term>
    <mesh_term>Protamines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

